Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.3% – Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded down 4.3% during trading on Friday . The company traded as low as $6.78 and last traded at $6.95. 5,451,801 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 15,227,077 shares. The stock had previously closed at $7.26.

Analysts Set New Price Targets

A number of analysts recently weighed in on RXRX shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Price Performance

The company has a market cap of $2.70 billion, a price-to-earnings ratio of -4.52 and a beta of 0.85. The company’s 50 day moving average price is $6.93 and its 200 day moving average price is $7.03. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.43) EPS. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the transaction, the director now directly owns 7,089,007 shares of the company’s stock, valued at approximately $47,283,676.69. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,288,380.78. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,341 shares of company stock worth $393,490. 15.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RXRX. Axxcess Wealth Management LLC grew its stake in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the last quarter. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Recursion Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after purchasing an additional 2,667 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.